AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27517656 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 14mg
Number of subjects: 32
Study 27517656 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 20mg
Number of subjects: 32
Study 27517656 — intervention group
Group type: COMPARATOR
Intervention: Perindopril 10-20mg
Number of subjects: 32
Study 24898653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention for 24 weeks
Number of subjects: 0
Study 23729104 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery and radiotherapy
Number of subjects: 26
Study 23729104 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery, radiotherapy, and additional chemotherapy
Number of subjects: 26
Study 20610445 — intervention group
Group type: EXPERIMENTAL
Intervention: Licofelone
Number of subjects: 161
Study 20610445 — intervention group
Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 161
Study 18512224 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly regimen (paclitaxel 100 mg/m² weekly for 3 of 4 weeks; carboplatin AUC = 6 mg/mL.min every 4 weeks)
Number of subjects: 136
Study 18512224 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen (paclitaxel 225 mg/m² every 3 weeks; carboplatin AUC = 6 mg/mL.min on Day 1 every 21 days)
Number of subjects: 136
Study 15994082 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated recovery protocol (Group A)
Number of subjects: 41
Study 15994082 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Group S)
Number of subjects: 41
Study 12495757 — intervention group
Group type: EXPERIMENTAL
Intervention: Painful heterotopic stimulation (cold pressor test, CPT)
Number of subjects: 12
Study 10989734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg/day for 8 weeks, with the possibility to increase treatment to Fosinopril + hydrochlorothiazide after 4 weeks
Number of subjects: 1243
Study 10989734 — intervention group
Group type: COMPARATOR
Intervention: Physicians aware of calculated cardiovascular risk
Number of subjects: 1243
Study 10989734 — intervention group
Group type: COMPARATOR
Intervention: Physicians unaware of calculated cardiovascular risk
Number of subjects: 1243
Study 8788082 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine dermal plaster (21 mg/24 h or 14 mg/24 h)
Number of subjects: 18
Study 8788082 — intervention group
Group type: COMPARATOR
Intervention: Placebo dermal plaster
Number of subjects: 18
Study 1634054 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg 5-ASA three times daily (n = 64)
Number of subjects: 125
Study 1634054 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 61)
Number of subjects: 125
Study 6229176 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin (15 mg/kg/dose)
Number of subjects: 37
Study 6229176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 37
Study 30126618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone (96 mg immediately after treatment followed by 48 mg each day for 5 consecutive days)
Number of subjects: 125
Study 30126618 — intervention group
Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 125
Study 26395742 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher miR-27b
Number of subjects: 300
Study 26395742 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher miR-320a
Number of subjects: 300
Study 24692737 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine (5 mg pilocarpine three times daily, n=5)
Number of subjects: 11
Study 24692737 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution intake, n=6)
Number of subjects: 11
Study 23187989 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope
Number of subjects: 23
Study 23187989 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 23
Study 20019680 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Counseling with medical assistants (8 visits over 6 months)
Number of subjects: 50
Study 20019680 — intervention group
Group type: COMPARATOR
Intervention: Control group (quarterly PCP visits and weight loss materials)
Number of subjects: 50
Study 18520796 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 18520796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15788496 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVBP (doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone) plus sequential consolidation
Number of subjects: 647
Study 15788496 — intervention group
Group type: COMPARATOR
Intervention: CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus involved-field radiotherapy
Number of subjects: 647
Study 14575974 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR testing for Borrelia sp
Number of subjects: 361
Study 10826429 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel preparation with oral polyethylene glycol electrolyte solution
Number of subjects: 267
Study 10826429 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation
Number of subjects: 267
Study 8865111 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenoprotein P
Number of subjects: 38
Study 8865111 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular glutathione peroxidase (eGSHPx)
Number of subjects: 38
Study 8865111 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma selenium
Number of subjects: 38
Study 1641820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg/24 h alteplase
Number of subjects: 32
Study 1641820 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg/24 h alteplase
Number of subjects: 32
Study 1641820 — intervention group
Group type: COMPARATOR
Intervention: Control venogram
Number of subjects: 32
Study 1641820 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding incidents
Number of subjects: 32
Study 6352952 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 19
Study 6352952 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation exercises
Number of subjects: 19
Study 6352952 — intervention group
Group type: COMPARATOR
Intervention: Maze-solving task
Number of subjects: 19
Study 30644260 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-segment fixation combined with vertebral reconstruction (treatment group)
Number of subjects: 53
Study 30644260 — intervention group
Group type: COMPARATOR
Intervention: Short-segment fixation (control group)
Number of subjects: 53
Study 30644260 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study 30644260 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 30265043 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 156
Study 30265043 — intervention group
Group type: COMPARATOR
Intervention: Literature control condition
Number of subjects: 156
Study 27247511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 µg/kg IV loading dose followed by 0.5 µg/kg/hr infusion)
Number of subjects: 60
Study 27247511 — intervention group
Group type: COMPARATOR
Intervention: Saline (normal saline infusion)
Number of subjects: 60
Study 24058179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care
Number of subjects: 712
Study 24058179 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 712
Study 22310648 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of standardized ECG criteria tool
Number of subjects: 60
Study 22310648 — intervention group
Group type: COMPARATOR
Intervention: Baseline interpretation without standardized ECG criteria
Number of subjects: 60
Study 22310648 — intervention group
Group type: COMPARATOR
Intervention: Comparison of cardiologists versus all other physicians
Number of subjects: 60
Study 20872929 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg per day) for 24 weeks
Number of subjects: 42
Study 20872929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20872929 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 42
Study 18065586 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron (DI) foodLETs (10 mg)
Number of subjects: 244
Study 18065586 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multiple-micronutrients (DMM) foodLETs (10 mg Fe)
Number of subjects: 244
Study 18065586 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly multiple-micronutrient (WMM) foodLETs (20 mg Fe)
Number of subjects: 244
Study 18065586 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo
Number of subjects: 244
Study 10832624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated magnetic resonance imaging (MRI) measuring early diastolic inflow velocity in the antero-posterior transverse direction of the LV.
Number of subjects: 10
Study 10832624 — intervention group
Group type: EXPERIMENTAL
Intervention: Gated magnetic resonance imaging (MRI) measuring early diastolic inflow velocity along the long axis of the LV.
Number of subjects: 10
Study 10832624 — intervention group
Group type: COMPARATOR
Intervention: Control group of age-matched healthy volunteers (10 subjects).
Number of subjects: 10
Study 9174485 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-fat foods (RF)
Number of subjects: 49
Study 9174485 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-sugar foods (RS)
Number of subjects: 49
Study 9174485 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 49
Study 9174485 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 49
Study 1371665 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (total dose, 6 to 7 x 10(6) KIU)
Number of subjects: 20
Study 1371665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1371665 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20
Study 3083919 — intervention group
Group type: COMPARATOR
Intervention: 5 minute consultation interval
Number of subjects: 0
Study 3083919 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 minute consultation interval
Number of subjects: 0
Study 3083919 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 minute consultation interval
Number of subjects: 0
Study 30522524 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 919
Study 30522524 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (AA)
Number of subjects: 919
Study 30522524 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 919
Study 30522524 — intervention group
Group type: EXPERIMENTAL
Intervention: PRRD1 and PRRD2
Number of subjects: 919
Study 30522524 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT estimates from linear regression equations for PRRD1 and PRRD2
Number of subjects: 919
Study 30522524 — intervention group
Group type: EXPERIMENTAL
Intervention: DHP treatment
Number of subjects: 919
Study 30522524 — intervention group
Group type: EXPERIMENTAL
Intervention: Age > 30 months, haematocrit ≥31%, body temperature > 37.4 °C, parasitaemia > 100,000/μl, PRRD1 value > 1000, no gametocytaemia
Number of subjects: 919
Study 30522524 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT estimates and PCTs determined by microscopy
Number of subjects: 919
Study 27230605 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P/C (nab-paclitaxel 100 mg/m2 on days 1, 8, and 15 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Number of subjects: 61
Study 27230605 — intervention group
Group type: COMPARATOR
Intervention: sb-P/C (solvent-based paclitaxel 200 mg/m2 on day 1 + carboplatin at AUC 6 mg·min/mL on day 1 every 3 weeks)
Number of subjects: 61
Study 27230605 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P/C
Number of subjects: 61
Study 27230605 — intervention group
Group type: COMPARATOR
Intervention: sb-P/C
Number of subjects: 61
Study 25422587 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) - 3 sessions of 30 minutes each over 6 weeks, n=26
Number of subjects: 54
Study 25422587 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 54
Study 25422587 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 54
Study 22750166 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring group (group A, n=63)
Number of subjects: 126
Study 22750166 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B, n=63)
Number of subjects: 126
Study 20082723 — intervention group
Group type: EXPERIMENTAL
Intervention: Long symptom duration
Number of subjects: 179
Study 20082723 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse KPS at baseline
Number of subjects: 179
Study 20082723 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender, body mass index, arch height
Number of subjects: 179
Study 20082723 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, worst pain, FIQ, step downs
Number of subjects: 179
Study 19391466 — intervention group
Group type: EXPERIMENTAL
Intervention: Family group decision-making programs (FGDM)
Number of subjects: 110
Study 19391466 — intervention group
Group type: COMPARATOR
Intervention: Traditional services
Number of subjects: 110
Study 15997202 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Orlistat-Exercise (DOE) group
Number of subjects: 24
Study 15997202 — intervention group
Group type: COMPARATOR
Intervention: Diet-Orlistat (DO) group
Number of subjects: 24
Study 12808225 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined training (aerobic + resistance)
Number of subjects: 30
Study 12808225 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 30
Study 12808225 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 10577701 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated regimen of 59.4 Gy, 1.8 Gy b.i.d over 24 days
Number of subjects: 191
Study 10577701 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation at 2 Gy/fraction per day, 70 Gy over 47 days
Number of subjects: 191
Study 8699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (800 mg 5 times/day) and prednisolone (0.7 mg/kg for the first 4 days, reduced by 0.1 mg/kg on consecutive days for another 6 days)
Number of subjects: 94
Study 8699062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 8699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir and prednisolone
Number of subjects: 94
Study 1896168 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (topical medication)
Number of subjects: 0
Study 1896168 — intervention group
Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 0
Study 31612327 — intervention group
Group type: EXPERIMENTAL
Intervention: A-PRF+
Number of subjects: 50
Study 31612327 — intervention group
Group type: COMPARATOR
Intervention: No A-PRF+
Number of subjects: 50
Study 31153846 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold (BVS)
Number of subjects: 2100
Study 31153846 — intervention group
Group type: COMPARATOR
Intervention: Xience everolimus-eluting metallic stent (EES)
Number of subjects: 2100
Study 28168204 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2000
Study 28168204 — intervention group
Group type: COMPARATOR
Intervention: Conventional lifestyle intervention
Number of subjects: 2000
Study 28168204 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg Pioglitazone
Number of subjects: 2000
Study 28168204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 25526875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 850 mg daily for 7 days, then 850 mg twice a day for the next 5 weeks
Number of subjects: 114
Study 25526875 — intervention group
Group type: COMPARATOR
Intervention: Placebo prescribed in a similar frequency
Number of subjects: 114
Study 25526875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 114
Study 25526875 — intervention group
Group type: COMPARATOR
Intervention: Metformin and Placebo
Number of subjects: 114
Study 23922647 — intervention group
Group type: EXPERIMENTAL
Intervention: ivacaftor (Kalydeco™; VX-770)
Number of subjects: 39
Study 23922647 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 20972569 — intervention group
Group type: EXPERIMENTAL
Intervention: gadobutrol
Number of subjects: 40
Study 20972569 — intervention group
Group type: COMPARATOR
Intervention: gadoterate meglumine
Number of subjects: 40
Study 19298459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg day(-1)) added to sulfonylurea
Number of subjects: 638
Study 19298459 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15-45 mg day(-1)) added to metformin
Number of subjects: 638
Study 19298459 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (80-320 mg day(-1)) + metformin
Number of subjects: 638
Study 19298459 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (80-320 mg day(-1)) + pioglitazone
Number of subjects: 638
Study 17914131 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich diet
Number of subjects: 11
Study 17914131 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-rich breakfast
Number of subjects: 11
Study 17914131 — intervention group
Group type: EXPERIMENTAL
Intervention: High-SAT breakfast
Number of subjects: 11
Study 17914131 — intervention group
Group type: COMPARATOR
Intervention: CHO-rich breakfast
Number of subjects: 11
Study 17914131 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO-rich diet
Number of subjects: 11
Study 16192421 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose hemodialysis
Number of subjects: 0
Study 16192421 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose hemodialysis
Number of subjects: 0
Study 12145995 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR 600 mg/body/day for 6 months and TAM 20 mg/body/day for 2 years (Group A)
Number of subjects: 550
Study 12145995 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐DFUR 600 mg/body/day for 2 years and TAM 20 mg/body/day for 2 years (Group B)
Number of subjects: 550
Study 12145995 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (2 Gy x 5 times/week, for 5 weeks)
Number of subjects: 550
Study 9988292 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Visit Education Program (FVEP)
Number of subjects: 66
Study 9988292 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 66
Study 7484859 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 12
Study 1968323 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 100 mg od
Number of subjects: 7
Study 1968323 — intervention group
Group type: EXPERIMENTAL
Intervention: propranolol (slow release) 160 mg od
Number of subjects: 7
Study 1968323 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 5 mg tid
Number of subjects: 7
Study 1968323 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg od
Number of subjects: 7
Study 1968323 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 7295463 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (100 mg)
Number of subjects: 6
Study 7295463 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 6
Study 7295463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30475424 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐BFRE
Number of subjects: 14
Study 30475424 — intervention group
Group type: COMPARATOR
Intervention: NF‐BFRE
Number of subjects: 14
Study 27342579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide 1.0-3.0 g/day
Number of subjects: 549
Study 27342579 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate 2.4-14.4 g/day
Number of subjects: 549
Study 27342579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucroferric oxyhydroxide
Number of subjects: 549
Study 27342579 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer carbonate
Number of subjects: 549
Study 25584664 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisector, multilevel intervention targeting improvements in fruit, vegetable, and water consumption; physical activity; and quality sleep.
Number of subjects: 1200
Study 23692829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive compact fluorescent tube (CFT) phototherapy
Number of subjects: 43
Study 23692829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive light-emitting diode (LED) phototherapy
Number of subjects: 43
Study 23692829 — intervention group
Group type: COMPARATOR
Intervention: Both CFT and LED phototherapy
Number of subjects: 43
Study 21849731 — intervention group
Group type: EXPERIMENTAL
Intervention: Stretching and strengthening exercises
Number of subjects: 40
Study 21849731 — intervention group
Group type: EXPERIMENTAL
Intervention: Scapular stabilization exercises
Number of subjects: 40
Study 21849731 — intervention group
Group type: COMPARATOR
Intervention: Control group (Stretching and strengthening exercises)
Number of subjects: 40
Study 19267352 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-peptide vaccination with 11 HLA‐A*0201‐restricted and two HLA class II synthetic peptides, administered subcutaneously for 18 months or until PSA progression, combined with various adjuvants including imiquimod, GM‐CSF, mucin‐1‐mRNA/protamine complex, and local hyperthermia.
Number of subjects: 19
Study 19267352 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod and mucin‐1‐mRNA/protamine complex as adjuvants (both are Toll‐like receptor‐7 agonists).
Number of subjects: 19
Study 19267352 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-peptide vaccination
Number of subjects: 19
Study 16696840 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-world navigation
Number of subjects: 0
Study 14759451 — intervention group
Group type: COMPARATOR
Intervention: Full-dose aprotinin
Number of subjects: 0
Study 14759451 — intervention group
Group type: COMPARATOR
Intervention: Half-dose aprotinin
Number of subjects: 0
Study 14759451 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 11725730 — intervention group
Group type: EXPERIMENTAL
Intervention: OC containing 0.030 mg of ethinyl estradiol (EE) and 0.15 mg of desogestrel (Group A)
Number of subjects: 64